GamaMabs Pharma SA
http://www.gamamabs.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From GamaMabs Pharma SA
Deal Watch: AbbVie Pursues Novel Neuropsychiatric Drug Class With Gilgamesh
Plus transactions involving Sanofi/Fulcrum, Reneo/OnKure, Lilly/Mitsubishi Tanabe, Lantern/Oregon, Zydus/Eiger and more.
Deal Watch: AZ, Alchemab To Study Immune Response For Novel Cancer Targets
Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.
GamaMabs’ Glyco-Engineered Murlentamab Shows Promise in Colorectal, Gynecological Cancers
Murlentamab Phase II results indicate its potential for use in combination with chemotherapy or other immunological agents, to target AMHRII-expressing tumors.
Start-Up Previews, April 2014
This Month's Profile Group, Antibodies Evolve, features profiles of GamaMabs, Numab, and Zebra Biologics. Plus these Start-Ups Across Health Care: CoolCore Biomedical Technologies, EBS Technologies, and Xeltis.
Company Information
- Industry
- Biotechnology
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice